1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Menopausal Disorders - Pipeline Review, H2 2013

Menopausal Disorders - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 39 pages

Menopausal Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Menopausal Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders. Menopausal Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Menopausal Disorders.
- A review of the Menopausal Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Menopausal Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Menopausal Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Menopausal Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Menopausal Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Menopausal Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Menopausal Disorders 7
Menopausal Disorders Therapeutics under Development by Companies 9
Menopausal Disorders Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Menopausal Disorders Therapeutics - Products under Development by Companies 15
Menopausal Disorders Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Menopausal Disorders Therapeutics Development 17
Paladin Labs Inc. 17
Pantarhei Bioscience BV 18
EndoCeutics, Inc. 19
Menopausal Disorders - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
(estradiol + testosterone) - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
BLACE - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
(prasterone + acolbifene) - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
(estradiol + progesterone) - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Troglitazone Compounds For Climacteric And Cancer - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Menopausal Disorders Therapeutics - Drug Profile Updates 31
Menopausal Disorders Therapeutics - Dormant Products 32
Menopausal Disorders - Product Development Milestones 33
Featured News and Press Releases 33
Aug 07, 2012: TherapeuticsMD Announces FDA Accepts IND Application For TX12002HR 33
Jun 25, 2010: Merck Challenges Verdict in Federal FOSAMAX (alendronate sodium) Trial 33
Jun 07, 2010: Statement on FOSAMAX (alendronate sodium) Product Liability Trial in U.S. District Court 33
May 05, 2010: Merck Wins Second Federal FOSAMAX (alendronate sodium) Bellwether Trial 34
Dec 14, 2009: Ablynx Initiates Phase I Trial Study Of ALX-0141 For The Treatment Of Postmenopausal Women 34
Nov 23, 2009: Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX (alendronate sodium) 35
Sep 11, 2009: Mistrial Declared in First Federal FOSAMAX Trial 35
Sep 03, 2009: Bionovo To Present Positive Results From Phase 2 Trial Of Menerba For Vasomotor Symptoms To The International Community 36
Jul 29, 2009: Statement by Merck and Co., Inc., Regarding FOSAMAX (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw 37
Mar 12, 2008: Wyeth withdrew EU medicines agency application to approve Pristiq 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39



List of Tables

Number of Products Under Development for Menopausal Disorders, H2 2013 7
Products under Development for Menopausal Disorders - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Paladin Labs Inc., H2 2013 17
Pantarhei Bioscience BV, H2 2013 18
EndoCeutics, Inc., H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Assessment by Combination Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Menopausal Disorders Therapeutics - Drug Profile Updates 31
Menopausal Disorders Therapeutics - Dormant Products 32



List of Figures

Number of Products under Development for Menopausal Disorders, H2 2013 7
Products under Development for Menopausal Disorders - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 20
Assessment by Combination Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25



Companies Mentioned

Paladin Labs Inc.
Pantarhei Bioscience BV
EndoCeutics, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016’, provides ...

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Adrenocorticotropic Hormone ...

Lupus Nephritis - Pipeline Review, H2 2016

Lupus Nephritis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Lupus Nephritis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Lupus Nephritis - Pipeline Review, H2 2016’, provides an overview of the Lupus Nephritis pipeline landscape. The report ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.